Revolution Medicines, Inc.: Pancreatic Neoplasms trials

The registry lists 13 Pancreatic Neoplasms studies with Revolution Medicines, Inc. as lead sponsor. 9 are open to participants now and 1 have results posted.

Phase 1 7Phase 2 4Phase 3 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingNCT07805954Phase 3
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingNCT07621718Phase 3
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07491445Phase 3
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingNCT07349537Phase 1
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingNCT07252232Phase 3
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/2
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingNCT06040541Phase 1
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT05379985Phase 1/2
• Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2Results posted
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaApproved for marketingNCT07573215
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingNCT06625320Phase 3
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 1